Moderna Inc (MRNA)

NASDAQ
Currency in USD
Disclaimer
125.36
+2.75
(+2.24%)
Real-time Data
Earnings results expected in 15 days
Day's Range
123.22
126.78
52 wk Range
115.03
217.25
Volume
1,604,642
Prev. Close
122.61
Open
123.49
Day's Range
123.22-126.78
52 wk Range
115.03-217.25
Volume
1,604,642
Average Vol. (3m)
3,134,547
1-Year Change
-24.96%
Shares Outstanding
381,209,341
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
203.90
Upside +62.46%

Moderna Inc Company Profile

Moderna, Inc. is a biotechnology company. The Company is focused on developing messenger ribonucleic acid (mRNA) therapeutics and vaccines. It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range spectrum of diseases. The Company's products include Spikevax, the Moderna COVID-19 vaccine (mRNA-1273), a bivalent vaccine targeting the BA.1 Omicron variant, combined with Spikevax (mRNA-1273.214), and bivalent vaccine targeting the BA.4/BA.5 Omicron variants combined with Spikevax (mRNA-1273.222). It has a development pipeline of 45 development candidates across its 48 development programs, of which 38 are in clinical studies.